<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-83989</identifier>
<setSpec>0213-005X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: Meta-analysis of randomized controlled clinical trials</dc:title>
<dc:description xml:lang="en">Objective To compare the incidence of severe hepatitis in HIV-infected patients receiving rifampicin plus pyrazinamide (RZ) for antituberculosis prophylaxis with that of patients receiving a conventional isoniazid-based regime for 6 to 12 months (6&#150;12H).Methods Meta-analysis of randomized controlled trials, in which RZ was compared with 6&#150;12H, the standard regimen for latent tuberculosis infection in HIV-infected patients. A systematic search of studies published between 1986 and 2007 was carried out, and 5 randomized clinical trials conducted in Spain (2), the USA (1), Haiti (1), and Zambia (1) were identified. The absence or presence of severe hepatoxicity, which was defined as toxicity causing the death of the patient or requiring treatment withdrawal, was assessed as a binary response, and the outcome measure was the difference in the risk of hepatotoxicity between patients receiving RZ and those receiving 6&#150;12H (controls).Result sAmong the 5 trials retrieved, 1 was excluded from the final analysis because of incomplete data on the development of hepatotoxicity. A final total of 2657 (..) (AU)</dc:description>
<dc:creator>Gallo, Marina</dc:creator>
<dc:creator>Castón, Juan José</dc:creator>
<dc:creator>García-Lázaro,  Milagros</dc:creator>
<dc:creator>Natera,  Clara</dc:creator>
<dc:creator>Kindelán,  José María</dc:creator>
<dc:creator>Camacho,  Ángela</dc:creator>
<dc:creator>Rivero,  Antonio</dc:creator>
<dc:creator>Pérez-Camacho,  Inés</dc:creator>
<dc:creator>Torre-Cisneros, Julián</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo Comparar la incidencia de hepatitis grave asociada al tratamiento con rifampicina más pirazinamida (RZ) en tratamiento preventivo de tuberculosis en pacientes infectados por virus de la inmunodeficiencia humana (VIH), con pauta estándar de isoniacida (H) durante 6 (6H) o 12 (12H) meses. Pacientes y métodos Metaanálisis de ensayos clínicos de asignación aleatorizada y controlados, en los que se comparó el régimen RZ con la pauta estándar de tratamiento de la infección latente tuberculosa (6 a 12H) en pacientes infectados por VIH. Se realizó una búsqueda sistemática de la literatura médica desde 1986 hasta diciembre de 2007. Se identificaron 5 ensayos clínicos de asignación aleatorizada y controlados, realizados en España, EE. UU., Haití y Zambia. Se valoró como repuesta binaria la ausencia o presencia de hepatotoxicidad grave, definida como aquella que provocó la muerte del paciente o fue causa de retirada del tratamiento, y se estableció como medida la diferencia de riesgo de (..) (AU)</dc:description>
<dc:source>Enferm Infecc Microbiol Clin;28(4): 239-244, abr. 2010. ilus, tab</dc:source>
<dc:identifier>ibc-83989</dc:identifier>
<dc:title xml:lang="es">Usar rifampicina más pirazinamida en profilaxis antituberculosa no incrementa el riesgo de hepatotoxicidad grave en pacientes infectados por virus de la inmunodeficiencia humana: metaanálisis de ensayos clínicos aleatorizados y controlados</dc:title>
<dc:subject>^d24718^s22012</dc:subject>
<dc:subject>^d32857</dc:subject>
<dc:subject>^d24718^s22057</dc:subject>
<dc:subject>^d999^s22000</dc:subject>
<dc:subject>^d28567</dc:subject>
<dc:subject>^d30967</dc:subject>
<dc:subject>^d14778^s22054</dc:subject>
<dc:subject>^d33075^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7705^s22000</dc:subject>
<dc:subject>^d4417</dc:subject>
<dc:subject>^d999^s22073</dc:subject>
<dc:subject>^d12154^s22073</dc:subject>
<dc:subject>^d999^s22020</dc:subject>
<dc:subject>^d4419</dc:subject>
<dc:subject>^d12154^s22020</dc:subject>
<dc:subject>^d7705^s22073</dc:subject>
<dc:subject>^d12154^s22000</dc:subject>
<dc:subject>^d7705^s22020</dc:subject>
<dc:subject>^d24852^s22083</dc:subject>
<dc:subject>^d33075^s22020</dc:subject>
<dc:type>article</dc:type>
<dc:date>201004</dc:date>
</metadata>
</record>
</ibecs-document>
